Iradimed (IRMD) Q2 Revenue Jumps 14%
Iradimed Corporation (NASDAQ:IRMD), a medical device maker specializing in MRI-compatible infusion pumps and patient monitoring systems, reported its second quarter 2025 earnings on August 1, 2025. The headline news was another round of record revenue and profit, with revenue of $20.41 million and non-GAAP earnings per share of $0.49. These results comfortably topped analyst forecasts, which had called for $20.01 million in revenue and $0.435 in non-GAAP EPS. Compared to the guidance issued last quarter, both revenue and non-GAAP EPS also exceeded the company’s own expectations. The period marked the company’s sixteenth straight quarter of record revenue. Management described the quarter as one of operational strength, while also flagging the planned completion of a new manufacturing facility and raising expectations for the full fiscal 2025 year.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Iradimed Corporation designs and markets devices for use in magnetic resonance imaging (MRI) environments, focusing on products that are safe around powerful magnetic fields. Its core offerings include the MRidium 3860+ IV Infusion Pump System, which enables the delivery of fluids or medications to patients during MRI scans, and the 3880 MRI-Compatible Patient Vital Signs Monitoring System, designed to track essential health metrics without electromagnetic interference.
Source Fool.com
